What are the recommendations for CAR T-cell therapy in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL)?

Updated: Jun 12, 2019
  • Author: Francisco J Hernandez-Ilizaliturri, MD; Chief Editor: Koyamangalath Krishnan, MD, FRCP, FACP  more...
  • Print
Answer

Answer

CAR T-cell therapy (treatment goal = cure):

Tisagenlecleucel 0.6-6 x 10^8 CAR-positive viable T cells/kg IV infusion at rate of 10-20 mL/min; administer 2-11 days after completing lymphodepleting chemotherapy [23, 24]

Axicabtagene ciloleucel 2 x 10^6 CAR-positive viable T cells/kg body weight, not to exceed 2 x 10^8 CAR-positive viable T cells; infuse IV over 30 min 3 days after completing lymphodepleting chemotherapy [25]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!